Alanyl-glutamine restores tight junction organization after disruption by a conventional peritoneal dialysis fluid
Ημερομηνία
2020Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Understanding and targeting the molecular basis of peritoneal solute and protein transport is essential to improve peritoneal dialysis (PD) efficacy and patient outcome. Supplementation of PD fluids (PDF) with alanyl-glutamine (AlaGln) increased small solute transport and reduced peritoneal protein loss in a recent clinical trial. Transepithelial resistance and 10 kDa and 70 kDa dextran transport were measured in primary human endothelial cells (HUVEC) exposed to conventional acidic, glucose degradation products (GDP) containing PDF (CPDF) and to low GDP containing PDF (LPDF) with and without AlaGln. Zonula occludens-1 (ZO-1) and claudin-5 were quantified by Western blot and immunofluorescence and in mice exposed to saline and CPDF for 7 weeks by digital imaging analyses. Spatial clustering of ZO-1 molecules was assessed by single molecule localization microscopy. AlaGln increased transepithelial resistance, and in CPDF exposed HUVEC decreased dextran transport rates and preserved claudin-5 and ZO-1 abundance. Endothelial clustering of membrane bound ZO-1 was higher in CPDF supplemented with AlaGln. In mice, arteriolar endothelial claudin-5 was reduced in CPDF, but restored with AlaGln, while mesothelial claudin-5 abundance was unchanged. AlaGln supplementation seals the peritoneal endothelial barrier, and when supplemented to conventional PD fluid increases claudin-5 and ZO-1 abundance and clustering of ZO-1 in the endothelial cell membrane. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Glucose Derivative Induced Vasculopathy in Children on Chronic Peritoneal Dialysis
Bartosova M., Zhang C., Schaefer B., Herzog R., Ridinger D., Damgov I., Levai E., Marinovic I., Eckert C., Romero P., Sallay P., Ujszaszi A., Unterwurzacher M., Wagner A., Hildenbrand G., Warady B.A., Schaefer F., Zarogiannis S.G., Kratochwill K., Schmitt C.P. (2021)RATIONALE: Patients with chronic kidney disease (CKD) have an exceedingly high cardiovascular risk; which further increases in patients on peritoneal dialysis (PD). The pathophysiological role of reactive metabolites ... -
Gross calcification of the small bowel in a continuous ambulatory peritoneal dialysis patient with sclerosing peritonitis
Poultsidi, A.; Liakopoulos, V.; Eleftheriadis, T.; Zarogiannis, S.; Bouchlariotou, S.; Stefanidis, I. (2006)We present here the case of a continuous ambulatory peritoneal dialysis (CAPD) patient who developed sclerosing calcifying peritonitis with gross macroscopic calcification of the small bowel, a rare and life-threatening ... -
Combination of exercise training and dopamine agonists in patients with RLS on dialysis: A randomized, double-blind placebo-controlled study
Giannaki C.D., Sakkas G.K., Karatzaferi C., Maridaki M.D., Koutedakis Y., Hadjigeorgiou G.M., Stefanidis I. (2015)Both exercise training and treatment with dopamine agonists (DA) have been used with success for the amelioration of uremic restless legs syndrome (RLS) symptoms. However, no data are available combining those two approaches. ...